Platelets play a critical role in hemostasis with aberrant function implicated in trauma-induced coagulopathy. However, the impact of massive transfusion protocols on platelet function during trauma hemorrhage is unknown. The aim of this study was to characterize the effects of platelet transfusion on platelet aggregation and fibrinolytic markers during hemostatic resuscitation.
H emorrhage is the principal cause of preventable death due to injury. 1 Contemporary damage-control resuscitation is characterized by expedited hemorrhage control with simultaneous and empiric transfusion of blood and blood products in high ratios. 2 Maintaining hemostatic potential through early administration of plasma and platelets in high volumes alongside transfusion of packed red blood cells (PRBCs) minimizes dilutional coagulopathy and is associated with improved outcomes. 3 However, the effects of platelet transfusions remain unclear, whereas the provision of platelet transfusions can be challenging. Platelet function is known to be reduced in trauma-induced coagulopathy (TIC), 4, 5 but the effects of platelet transfusion on coagulation during active bleeding are unknown. This knowledge gap has been highlighted by several contemporary major hemorrhage guidelines. 6, 7 Platelets promote coagulation primarily by adhering to the endothelium or subendothelium to form aggregates at sites of vascular injury and by providing a phospholipid platform to support thrombin generation. 8 Hemostasis is further amplified through the release of reactive mediators from platelet storage granules into the plasma space, 9 including clotting factors and mediators of fibrinolysis. In particular, platelets contain a large pool of plasminogen activator inhibitor-1 (PAI-1) 10 and alpha-2 antiplasmin (A2AP), 11 which are hypothesized to represent an important mechanism through which platelets attenuate tissue plasminogen activator (tPA)-mediated fibrinolysis in vitro. 12, 13 Impaired platelet aggregation is common after severe injury and associated with increased mortality, although the mechanisms of this remain unknown. [14] [15] [16] Attempts to support platelet function through transfusion of allogeneic platelets during major hemorrhage therefore seems logical, but to date, no studies have evaluated how platelet transfusions affect hemostasis during bleeding in trauma patients.
Our working hypothesis was that platelet transfusions exert their effects either through augmenting aggregation, promoting thrombin generation or by the release of granule contents into the plasma space. In this study, our objectives were to describe changes in whole-blood platelet aggregation, rotational thromboelastometry (ROTEM), circulating levels of platelet-derived clotting factors, and plasma markers of fibrinolysis resulting from platelet transfusion. We compared interval changes in bleeding trauma patients receiving blood component therapy with and without platelets.
PATIENTS AND METHODS

Study Design and Participants
Patients recruited into the Activation of Coagulation and Inflammation in Trauma (ACIT) II (UK CRN ID 5637) prospective, observational study at an urban major trauma center in the United Kingdom between January 2008 and November 2015 were eligible for inclusion. Entry and exclusion criteria for ACIT II have been published in detail previously. 17 The study was approved by the local research ethics committee (reference 07/Q0603/29). For this study, patients who received less than four units of PRBCs were retrospectively excluded to focus on bleeding patients who received platelet transfusions and to allow longitudinal analyses during bleeding. Assent for patient recruitment was initially provided by an independent physician, with written informed consent obtained from a patient or relative as soon as possible after enrollment.
Major Hemorrhage Protocol
At our institution, activation criteria for the MHP are a systolic blood pressure less than 90 mm Hg, poor response to initial fluid resuscitation and/or clinical suspicion of active hemorrhage. MHP activation occurs either from a scene by the physician-led prehospital care team or upon arrival in the emergency department (ED) by the trauma team leader. Empiric transfusion with a fresh-frozen plasma (FFP)-platelet-PRBC target ratio of 1:1:1 is initiated with "pack A," which contains four units of PRBCs and four units of FFP. Universal donor PRBCs and thawed FFP are available in ED for immediate transfusion. If bleeding continues, "pack B" and all subsequent packs provide six PRBCs, six FFPs, two pools of cryoprecipitate, and one apheresis unit of platelets; the order of administration of these products is at the discretion of the clinical team. The MHP was updated to include tranexamic acid (TXA) administration in February 2011 and prehospital transfusion of up to four units of PRBCs in January 2014.
Blood Sampling
Blood was drawn for research purposes within 20 minutes of arrival in ED from either the femoral vein or antecubital fossa, alongside routine laboratory tests. Blood product use before this initial sample draw was recorded. Platelet counts were measured with a Coulter LH750 hematology analyzer (Beckman Coulter, CA; normal range, 150-400 Â 10 9 /L). Point-of-care arterial blood gas analysis was performed to determine base deficit (BD) and lactate concentration. In patients who received transfusion of blood products, further samples were obtained after every fourth unit of PRBC, up to and including the 12th unit. Samples were processed by a member of the research team within 45 minutes of collection.
Platelet Aggregation and Thromboelastometry
Platelet aggregation was assayed in whole blood with multiple electrode impedance aggregometry using the Multiplate analyzer (Roche pharmaceuticals, Sussex, UK). Samples were processed according to the manufacturer's instructions. Briefly, blood was collected into a 3-mL vacutainer (Roche Pharmaceuticals) containing greater than 15 μg/mL hirudin. Aggregation was measured in 300 μL of blood over 6 minutes in response to 6.5 μM adenosine diphosphate (ADP), 0.5 mM arachidonic acid (AA), 3.2 μg/mL collagen and 32 μM thrombin-receptor activating peptide-6 (TRAP; final concentrations given). Results are reported as area under the curve in arbitrary units. Hypofunction and hyperfunction were defined according to references ranges stated by the manufacturer (570-1,130 U for ADP, 710-1,150 U for AA, 720-1,250 U for collagen, and 840-1,280 U for TRAP). ROTEM was performed on citrated whole blood using a ROTEM delta instrument in the presence of tissue factor (EXTEM) and with the addition of cytochalasin D, an inhibitor of platelet aggregation (FIBTEM).
Clotting Factors and Fibrinolytic Markers
For quantification of plasma coagulation protein levels, blood was drawn into 4.5 mL glass vacutainer containing 3.2% sodium citrate (Becton, Dickinson and Company, Plymouth, UK) and centrifuged at 1,750g for 10 minutes. The plasma component was then removed and recentrifuged at the same speed and duration before storage at −80°C. Immediately after thawing levels of factor II (reference range, 70-146 IU/dL), factor V (66-114 IU/dL), factor XIII (55-158 IU/dL), D-dimer (0-440 ng/mL), von Willebrand antigen (50-160 IU/dL), soluble fibrin monomer complex (0-6 μg/mL), and A2AP (68-136 IU/dL) were quantified in the hospital laboratory with a Sysmex CS2100i automated analyzer (Sysmex, UK) according to standard protocols; results are reported in international units. Levels of PAI-1 (4-43 ng/mL), tPA (2-12 ng/mL), plasmin-antiplasmin (PAP) complex (120-700 μg/L), and prothrombin fragments 1 + 2 (PF 1 + 2) (69-229 pmol/L) were measured using sandwich enzyme-linked immunosorbent assay (Asserchrom, Diagnostica Stago).
Data Collection
Demographic data, injury characteristics, and physiologic variables were collected prospectively. Cessation of blood product transfusion was used as a surrogate of hemostasis for the purposes of this study. Daily follow-up was performed for the first 28 days of hospital stay or until death or discharge. Multiple organ dysfunction syndrome was defined as a Sequential Organ Failure Assessment score of 6 or greater.
Data Analysis
Data were analyzed separately to assess the effect of platelet transfusion on platelet aggregation, with a subgroup analysis to examine the changes in coagulation factors and ROTEM. First, to study the impact of platelet transfusion on platelet aggregation over time during resuscitation, patients were divided into two groups at each sampling point (4 units PRBC, 8 units PRBC, 12 units PRBC): (1) those that received a platelet transfusion and (2) those that did not receive a platelet transfusion before each sampling point. To mitigate the potential effects of selection bias, we divided patients into those who received a massive transfusion (MT) (defined as ≥ 10 PRBC units in 24 hours) and patients who required less than 10 PRBC units. Second, we divided all available four-unit PRBC intervals into three groups, depending on the blood products administered during this interval: PRBCs only; PRBCs and FFP; or PRBCs, FFP, and platelets. This approach was taken to isolate the effects of platelet transfusion on plasma protein levels and viscoelastic measurements from those of FFP. Interval changes were calculated by subtracting the value at the end of the interval from the value at the beginning of the interval.
Data analysis was performed using Excel v15.2 (Microsoft, CA) and Prism v6.0 (GraphPad software, CA). Normal-quantile plots were used to assess the distribution of continuous data. Data from nonparametric distributions are reported as median with interquartile range and were compared with the Mann-Whitney U test, Kruskall-Wallis test with Dunn's posttest, or Wilcoxon matched pairs test. Data from parametric distributions are presented as mean ± 95% confidence intervals and were compared with Student's or paired t test as applicable, or one-way analysis of variance with Tukey's post hoc test for multiple comparisons. Correlation was assessed with Spearman's coefficient. Categorical data are displayed as number and percentage and were compared with Fisher's exact test. A two-tailed p value less than 0.05 was considered significant for all comparisons.
RESULTS
One hundred sixty-one patients received at least four PRBCs and were included in the study (Fig. 1) . Eighty-two patients received PRBC transfusion before baseline sampling (median, one PRBC unit [0-2]). Patients who received platelets (n = 107) during the first 24 hours had similar injury severity to those who did not receive a platelet transfusion (n = 54) but were significantly more shocked, with longer length of hospital stay and increased rates of organ failure (Table 1) . A nonsignificant trend toward reduced mortality at 24 hours in patients receiving platelets was observed (platelets transfused, 8 [7%] of 107 vs. no platelets transfused 9 [17%] of 54; p = 0.10). Median time from admission to platelet transfusion was 90 (63-166) minutes and patients who required a platelet transfusion received significantly more blood and blood products (FFP, cryoprecipitate) during the first 24 hours (Table 1 ). The average ratio of platelets to PRBCs, assuming one apheresis unit to be equivalent to six units of PRBCs, was 0.3 between 0 and 4 PRBCs, 0.9 between 5 and 8 PRBCs, and 1.2 between 9 and 12 PRBCs.
On admission to ED, more than one in four patients who required over four PRBC units had evidence of reduced platelet aggregation in response to agonist stimulation: ADP, 70 (42%); AA, 59 (36%); collagen, 38 (24%); TRAP, 38 ( In patients who received a massive transfusion and had samples during hemorrhage, platelet aggregation declined significantly during resuscitation ( Fig. 2A-D (p > 0.05 at each sample time-point). At each sampling point, groups were comparable in terms of injury severity and depth of shock, although patients who received platelets tended to have samples taken later after admission (Table 2) . Aggregation in response to each of the agonists deteriorated at each sampling point during bleeding compared with baseline, and on average, by eight PRBC units had decreased from the admission value by 81% in patients who did not receive platelets and 78% in patients who had a platelet transfusion. Platelet count also declined during hemorrhage irrespective of platelet transfusion. After eight PRBC units, the platelet count in those who received platelets was 97 (71-106) Â 10 We next assessed the efficacy of platelet transfusion on ROTEM variables in a subset of patients who had plasma coagulation protein levels measured during bleeding at each four-unit PRBC interval (n = 89). Overall, 115 interval samples were available for analysis-FFP was administered in 85 intervals, of which 29 included at least one pool of platelets (Table 2) .
Compared with the main study cohort, this subgroup was more severely injured (Injury Severity Score, 34 [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] vs. 29 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] , p = 0.03) but had a similar degree of shock (BD, 8.9 ± 1.3 mmol/L vs. 9.8 ± 1.1 mmol/L, p = 0.31), PRBC transfusion (8 [6] [7] [8] [9] [10] [11] Comparing intervals in which platelets were transfused with those in which only FFP and PRBC were administered, there was no significant difference in viscoelastic measurement of clotting time, clot formation, or clot strength (Table 3) . However, platelet transfusion was associated with a significant reduction in EXTEM maximum lysis (ML) ( Table 3 and Fig. 3A ). Changes in circulating clotting factor levels were similar, irrespective of whether or not platelet transfusions were administered during a four-unit PRBC interval (Table 3) . Platelet transfusion during an interval was associated with a significant increase in circulating levels of PAI-1 compared with intervals in which PRBCs and FFP were administered (Fig. 3B) . Conversely, levels of soluble tPA decreased in intervals where platelets were transfused in combination with PRBCs and FFP (Fig. 3C ).
PAP complex levels declined in intervals containing PRBCs and FFP regardless of whether platelets were transfused (Fig. 3D) . No correlation was observed between interval duration and change in EXTEM ML (r = 0.13, p = 0.27), PAI-1 (r = 0.17, p = 0.19), or tPA (r = −0.07, p = 0.63). Overall, the only clear effects of platelet transfusions appeared to be a reduction in fibrinolysis with minimal effect on other functional aspects of hemostasis, including platelet aggregation.
DISCUSSION
In this prospective single-center cohort study, the strongest effect of platelet transfusion during trauma hemorrhage appears to be reduction of fibrinolysis without improvement in clot strength or clotting times. Administering platelets as part of a major hemorrhage protocol did not restore platelet aggregation or platelet count. Compared with transfusion of FFP and PRBC alone, platelets transfusions improved viscoelastic measures of fibrinolysis with increased plasma PAI-1 levels and reduced circulating tPA. In cohort studies, high platelet-PRBC ratios appear to be associated with improved outcomes. [18] [19] [20] The reduction in early deaths due to exsanguination in the 1:1:1 arm of the PROPPR randomized control trial may due to the effects of early platelet administration rather than (or as well as) the higher doses of blood components. Reduction of hyperfibrinolysis may be a key mechanism by which early platelet transfusion improves hemostasis in TIC.
Platelets contain a broad array of procoagulant and anticoagulant factors which are released into the plasma space upon activation. 9 Of particular relevance to the potential role of platelets in acute traumatic coagulopathy and TIC are inhibitors of fibrinolysis including PAI-1. Although the activity of plateletderived PAI-1 has been questioned, 21 recent evidence suggests that the active form is stored in large quantities within platelet alpha granules. 10 In acute traumatic coagulopathy, activated protein C-dependent fibrinolysis is thought to occur through inhibition of PAI-1, which allows tPA-mediated plasminogen cleavage to proceed unchecked. [22] [23] [24] Our findings suggest that transfusion of stored platelets may provide an important source of PAI-1, which forms an inactive complex with circulating tPA and hypothetically reduces the level of free tPA detectable in plasma. 25 FFP contains antiplasmin although platelet transfusion had an additive effect on reversal of functional fibrinolysis as demonstrated by a reduced ML. Although changes in PAP and D-dimer levels were not significantly different after platelet transfusions, this may be attributable to the long half-life of these biomarkers in the circulation. Both assays describe prior fibrinolytic activation rather than the dynamic changes in fibrinolysis during bleeding. 26 This apparent predominant effect of platelet transfusion is supported by in vitro evidence that platelet lysate attenuates tPA-dependent fibrinolysis 12 and raises the question of whether earlier administration of platelets could confer additional benefit particularly in patients with hyperfibrinolysis.
Trauma-induced platelet dysfunction on arrival to ED has been previously described by several authors, [14] [15] [16] and it is plausible that the conditions which impair the function of endogenous platelets may have the same effect on stored platelets administered in transfusion. Whether trauma-induced platelet dysfunction is an intrinsic platelet defect or the result of circulating conditions is unknown and requires further study. With regards to platelet count, it is possible that the rate of platelet loss through ongoing bleeding exceeded the number of platelets being administered in our patient cohort. Alternatively, stored platelets may form microaggregates or be recruited to thrombus formation, and thus escape detection by the laboratory platelet count. 27 These hypotheses remain speculative, however, and further investigation is required to determine how the postinjury intravascular milieu impacts on the function of both stored and endogenous platelets.
There are a number of limitations to this study, principally as a result of its observational design. First, comparisons of interval changes in clotting factor levels and viscoelastic tests could in theory be influenced by variations in the rate of blood loss and the time of sampling, which was slightly later after admission in patients receiving platelets. Second, given the sample sizes for each interval, we were unable to fully control for concomitant administration of FFP and cryoprecipitate. Third, we were not able to evaluate the effect of timing of platelet transfusion as part of our MHP. In particular, whether "up front" platelet transfusion, as administered in the 1:1:1 arm of the PROPPR trial, conferred additional hemostatic benefits could not be addressed in this study due to the design of the MHP at out institution. Platelets are delivered in the second MHP pack and therefore later in the clinical episode. Further work is required to assess other possible sources for the delayed rise in PAI-1 e.g. reperfusion injury of hypoperfused endothelium. Fourth, we did not directly measure thrombin generation potential but used PF 1 + 2 fragments in plasma as a surrogate. Platelet transfusion has been advocated as a method to support thrombin generation 28 although we found no significant difference in PF 1 + 2 fragments between groups. Fifth, we did not perform any functional coagulation tests on the apheresis platelet units themselves as this forms part of an ongoing study. Finally, we did not undertake a detailed evaluation of the impact of platelet transfusion on clinical outcomes although these have previously been described in larger multicenter studies. 3, 18 Our novel findings demonstrate a potential role for platelets in reducing fibrinolytic activity as measured by laboratory assays and requires clinical validation in larger trauma trials.
In conclusion, this study suggests that platelet transfusions given in standard doses as part of an MHP primarily reduce fibrinolysis but do not preserve either platelet aggregation or platelet count during bleeding. Platelets administered to bleeding trauma patients appear to have antifibrinolytic effects over and above FFP through inhibition of tPA-mediated fibrinolysis by providing an additional dose of PAI-1. Further work in larger cohorts is required to ascertain the impact of early platelet delivery during damage-control resuscitation, the role of platelet-derived clotting factors on reversing fibrinolysis, and potential improvements in outcomes from trauma hemorrhage. Whether earlier platelet transfusion has a particular hemostatic benefit in all, or selected bleeding patients, remains an important question and merits further investigation.
transfusion is associated with changes in laboratory values associated with coagulation.
They report on a seven-year prospective study, single center, of 1,042 patients that after exclusions resulted in 161 evaluated patients. I have several comments and questions, first the comments.
What do we know about platelet transfusion in trauma patients? After injury endogenous platelets don't work very well. Low platelet counts are associated with increased bleeding. Stored platelets don't work very well.
There is not a rapidly available, validated platelet function test. And stored platelets are the most available blood product, not requiring type and cross, thawing, before transfusing. And, lastly, transfused platelets stored for five or more days are associated with increased bacterial infection.
As the authors stated, we recently published the 12-center randomized PROPPR study where platelets and plasma and red cells were given in predetermined ratios. In the group where death from hemorrhage was significantly less, platelets were infused first.
As we say in the paper and the authors related, separating the effects of plasma and platelets when you do this 1:1 ratio or any ratio is extremely difficult, if not impossible.
As we look at coagulation lab tests I am more aware of how disassociated they can be from predicable clinical outcomes. Laboratory tests go up and down. But do these numbers correlate with clinical outcomes? Or, even more concerning, do they allow us to intervene rapidly, in a logical fashion, with a predictable clinical result?
Many of these coagulation tests are decades old and based on a conventional approach to the coagulation cascade that we no longer really believe represents what happens in vivo.
Further complicating this is the variability imposed by individual response to injury, individual blood product variability, individual patient response, variable use of crystalloid and artificial colloid, and, importantly, provider variability at the bedside of actually implementing their transfusion scheme.
It's no wonder these data are confusing. This field is in dire need of a precision medicine approach. I've got two questions.
The two groups were created post hoc and how the 1:1 transfusion scheme was implemented was decided upon by the individual physician. It appears that your physicians thought platelets were important and gave them to the sickest patients.
There is no correct way to time the blood draw in these patients. Your group has chosen to draw samples based on units of red cells transfused. And as you state in the paper, this ignores rate of transfusion. Rate of bleeding is really important.
What if the patient is bleeding rapidly and died early? This issue is documented by a lower massive transfusion rate of 4 percent but a much higher 24-hour mortality of 17 percent in the noplatelet group versus a higher massive transfusion rate and a lower 24-hour mortality in those that received platelets. My guess is that many of the no-platelet patients bled to death before reaching the arbitrary 10 unit transfusion.
Another possibility, of course, is that platelet transfusion, despite laboratory values or standard platelet function tests, really had an improved effect on the clinical outcome.
Did the authors try to create an adjusted model to account for the significant imbalance between your groups in your observational study over seven years?
The authors state they wonder about the efficacy of platelet transfusion on viscoelastic measures. What if the numbers get better and the patient still continues to bleed? What are we supposed to do?
It would seem reasonable to consider the relationship between bleeding, transfusion, laboratory values and clinical outcomes. Isn't it a bit risky to draw conclusions about a blood product without clinical outcomes?
The observation that platelet transfusions inhibit fibrinolysis is very interesting and may explain why TXA may not change outcomes in centers that utilize early blood product and platelet transfusion.
The authors have increased our knowledge about platelet transfusions in actively bleeding patients and their work opens new avenues of investigations and they are to be congratulated.
I would like to thank the society for the opportunity to discuss this paper. Thank you.
Dr. Juan Duchesne (Hammond, Louisiana): Paul, nicely done. Duchesne from Louisiana. I have a question/comment. Back when I was -just one question, okay. Quickly. If you look at the max clotting factor in the EXTEM and the FITEM before, during and after resuscitation you're going to see the V effect, meaning that that platelet is not really clotting, they're not sticking together.
And my question is that you are basically saying that that actually helps ----fibrinolysis. That's the take-home message for me. But what do you recommend for that group of patients?
I still give them a lot of platelets because it's telling me on the thromboelastogram that you need to and those patients are doing better. So were your group of patients that sick? Thank you.
Dr. Zsolt J. Balogh (Newcastle, Australia): Zsolt Balogh from Newcastle. Did you look at the storage age of your platelets that you transfused? And do you have the capacity to evaluate the stored platelet transfusions' platelet function? Thank you.
Dr. Paul Vulliamy (London, England): So, I'd like to thank everyone for their insightful comments and, in particular, Dr. Holcomb for really framing our work in the appropriate context.
With regards to the first question about imbalances between the two groups, obviously, this is a difficulty inherent in all observational studies of trauma patients.
In terms of our sampling approach, we opted for a unitbased sampling strategy really because we found that this allows us to look very early-on in the resuscitation.
So most of these samples, a vast majority were obtained within two hours so we can actually look at what is happening to coagulation during that three-hour window when the majority of hemorrhagic deaths occurred.
Obviously, there is going to be variation in rate of bleeding between patients but we believe that this is partially corrected for by the overall transfusion requirements in our patients.
Furthermore, for this analysis we've attempted as far as possible to compare like for like. So we tried to look at patients at particular stages of their resuscitation and compare their platelet aggregation between those two groups.
And, similarly, we've attempted to control for plasma. So although we haven't specifically created a model to look at this we feel that our analysis has, to some extent, mitigated these concerns.
With regards to the second question and the comments on mortality, I think I would completely agree that it would be very risky to draw conclusions based on this data alone.
However, I would say that really this mechanistic approach was designed to kind of complement the much-larger, more robust studies which have been carried out to look at this question of clinical outcomes, particularly the PROMMIT study and the PROPPR trial.
We feel that by developing our understanding of actually how these blood products are working we can, in the future, potentially inform the discussions as to when we should be giving them and even whether there are specific patients who could particularly benefit.
And that kind of brings me on to the first question in terms of how we can actually deliver products during the resuscitation and the effect of platelets.
We really, as Dr. Holcomb said, don't have reliable tests to tell us where, which products we should be giving. We know that ROTEM is, in terms of guiding platelet delivery, is perhaps not the best test. So I don't have an optimal answer for that.
I do think that this mechanistic data that we presented does suggest that perhaps if we are giving these platelets earlier-on, as was administered in the PROPPR trial, we could be doing better by our patients.
With regards to the second question, we didn't specifically look at the storage age of platelets but this is obviously an important point.
We plan further studies in vitro to look at the effectiveness of stored platelets in the trauma microenvironment and hopefully that should go some way to answering the question. But, clearly, it is beyond the scope of the data we presented here.
Thank you very much.
